Lunit said it plans to present 11 abstracts – eight oral and three poster presentations – related to artificial intelligence (AI) medical image analysis solutions during the Radiological Society of North America 2022 (RSNA 2022).
In particular, the company will disclose the results of real world data research that applied Lunit Insight MMG, a mammography image analysis solution, to actual medical sites.
“Unlike the existing retrospective studies conducted on records of the past that have already been prescribed, the upcoming presentation will be a prospective study conducted in the course of patient treatment,” the company said.
Other presentations involving Lunit Insight MMG include a study comparing the cancer diagnosis rate of Lunit Insight MMG and Lunit Insight Digital Breast Tomosynthesis, a three-dimensional (3D) mammography image analysis solution, a study evaluating the area under the curve of Lunit Insight MMG in women who have used a breast cancer screening program in a specific country.
The company will also make presentations related to Lunit Insight CXR, the chest X-ray image analysis solution, including a study on the results of lung nodule detection rates between the group either using or not using Lunit Insight CXR for examinees who received a health checkup at Korean hospitals.
Lunit said it will also unveil research presentations related to its next-generation new products during the conference.
"The company has confirmed the changed status of medical AI research in the academic field as eight out of 11 research abstracts that Lunit plans to present during RSNA 2022 were selected as oral presentations," Lunit CEO Suh Beom-seok said. "For the meaningful research results at the conference to lead to business results, Lunit plans to actively conduct business networking by setting up an exclusive booth at the RSNA 2022 exhibition hall."
RSNA, which celebrates its 108th anniversary, will be held from Nov. 27 to Dec. 1 in Chicago. It is the largest radiology conference in North America, with more than 50,000 people from around the world, including academics, medical experts, and biotechnology company officials, participating in the conference.